Literature DB >> 8557824

Limited T cell receptor usage by HTLV-I tax-specific, HLA class I restricted cytotoxic T lymphocytes from patients with HTLV-I associated neurological disease.

I Elovaara1, U Utz, S Smith, S Jacobson.   

Abstract

T cell receptor (TCR) V alpha and V beta chain usage of HTLV-I tax-specific, HLA class I restricted CD8+ cytotoxic T cells (CTL) was determined from lymphocytes obtained from peripheral blood of patients with HTLV-I associated neurological disease. To characterize TCR repertoire, CD8+ lymphocytes from peripheral blood were cloned in limiting dilution, and the resulting wells were screened for HTLV-I-specific precursor CTL activity. RNA was isolated from HLA-A2 restricted HTLV-I tax peptide-specific (tax 11-19; LLFGYPVYV) CD8+ CTL lines and cDNA was analyzed by PCR amplification using V alpha and V beta chain family-specific oligonucleotide primers. The results indicate that CD8+ cytotoxic T cell lines from HLA-A2 HAM/TSP patients express a limited repertoire of T cell receptor chains which may correlate with duration and severity of disease. The restricted use of TCR genes expressed by antigen-specific CTL may play a critical role in the pathogenesis of HAM/TSP and may be of value in developing immunotherapeutic strategies that focus on eliminating these cells or inhibiting their activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8557824     DOI: 10.1016/0165-5728(95)00129-8

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  7 in total

1.  Molecular Mechanisms of Neurodegenerative Diseases Induced by Human Retroviruses: A Review.

Authors:  Bryan P Irish; Zafar K Khan; Pooja Jain; Michael R Nonnemacher; Vanessa Pirrone; Saifur Rahman; Nirmala Rajagopalan; Joyce B Suchitra; Kate Mostoller; Brian Wigdahl
Journal:  Am J Infect Dis       Date:  2009-07-01

2.  Human CD4+ T lymphocytes recognize a highly conserved epitope of human T lymphotropic virus type 1 (HTLV-1) env gp21 restricted by HLA DRB1*0101.

Authors:  B Kitze; K Usuku; Y Yamano; S Yashiki; M Nakamura; T Fujiyoshi; S Izumo; M Osame; S Sonoda
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

3.  Conserved CDR3 regions in T-cell receptor (TCR) CD8(+) T cells that recognize the Tax11-19/HLA-A*0201 complex in a subject infected with human T-cell leukemia virus type 1: relationship of T-cell fine specificity and major histocompatibility complex/peptide/TCR crystal structure.

Authors:  K D Bourcier; D G Lim; Y H Ding; K J Smith; K Wucherpfennig; D A Hafler
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

4.  CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP.

Authors:  Wei Ju; Meili Zhang; Jian-kang Jiang; Craig J Thomas; Unsong Oh; Bonita R Bryant; Jing Chen; Noriko Sato; Yutaka Tagaya; John C Morris; John E Janik; Steven Jacobson; Thomas A Waldmann
Journal:  Blood       Date:  2010-11-24       Impact factor: 22.113

5.  Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism.

Authors:  Jing Chen; Mike Petrus; Bonita R Bryant; Vinh Phuc Nguyen; Mindy Stamer; Carolyn K Goldman; Richard Bamford; John C Morris; John E Janik; Thomas A Waldmann
Journal:  Blood       Date:  2008-03-13       Impact factor: 22.113

Review 6.  T cell receptor repertoire analysis in HTLV-1-associated diseases.

Authors:  Annaliese Clauze; Yoshimi Enose-Akahata; Steven Jacobson
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

7.  T cell receptor alpha variable 12-2 bias in the immunodominant response to Yellow fever virus.

Authors:  Amandine Bovay; Vincent Zoete; Garry Dolton; Anna M Bulek; David K Cole; Pierre J Rizkallah; Anna Fuller; Konrad Beck; Olivier Michielin; Daniel E Speiser; Andrew K Sewell; Silvia A Fuertes Marraco
Journal:  Eur J Immunol       Date:  2017-12-11       Impact factor: 5.532

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.